Metoclopramide Baxter

Metoclopramide, the active ingredient in Metoclopramide Baxter, is a dopamine antagonist presented as an injectable solution for intramuscular and intravenous use. It is employed to alleviate nausea, vomiting, and to promote gastrointestinal motility in adult patients, including postoperative care and gastroparesis management.

GNH USA supplies Metoclopramide Baxter as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide is used to manage conditions related to nausea, vomiting and delayed gastric emptying.

- Nausea and vomiting: reduces frequency and severity of episodes in various clinical situations. - Gastroparesis: enhances gastric emptying and improves related symptoms. - Postoperative nausea and vomiting: prevents and treats nausea after surgical procedures.

Metoclopramide may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Drowsiness - Fatigue - Restlessness - Diarrhea - Abdominal cramping - Headache

Serious or Rare Side Effects: - Tardive dyskinesia - Neuroleptic malignant syndrome - Severe depression - Seizures - Allergic reactions (including anaphylaxis) - Cardiac arrhythmias

When prescribing Metoclopramide, clinicians should consider several safety measures to minimize risk.

- Assess neurological history: evaluate for movement disorders or Parkinsonian symptoms. - Monitor for signs of depression or suicidal thoughts. - Use lowest effective dose: limit duration to avoid extrapyramidal effects. - Avoid in patients with known hypersensitivity to metoclopramide. - Caution in renal impairment: adjust dosing as needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Metoclopramide can interact with other medicines, requiring careful assessment.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Anticholinergic agents: may reduce prokinetic effect. - CYP2D6 inhibitors (e.g., fluoxetine): increase metoclopramide plasma levels.

Moderate Interactions (Monitor Closely): - Other dopamine antagonists: additive extrapyramidal risk. - Serotonergic drugs (e.g., ondansetron): potential serotonin syndrome. - CNS depressants (e.g., opioids, benzodiazepines): enhanced sedation.